XML 20 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1

Note 5 - Derivative Liabilities	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 5 - DERIVATIVE LIABILITIES In connection with the consummation of the Merger completed on February 12, 2016, the Company issued warrants to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share to Strategic Bio Partners for debt cancellation. In addition, upon the closing of the private placement transactions in April 2016, the Company issued 127,346 warrants, to the placement agent of the private offering to purchase the Company’s Series B Preferred Stock with an exercise price of $1.25 and a five -year term. The warrants have a cashless exercise feature that requires the Company to classify the warrants as derivative liabilities.

X

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140

+ Details

Name:	us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration